Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Dexcom Inc (NASDAQ: DXCM) closed at $125.81 up 1.18% from its previous closing price of $124.34. In other words, the price has increased by $1.18 from its previous closing price. On the day, 3.85 million shares were traded. DXCM stock price reached its highest trading level at $128.51 during the session, while it also had its lowest trading level at $123.075.
Ratios:
For a deeper understanding of Dexcom Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.39. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Dolan Matthew Vincent sold 1,990 shares for $137.81 per share. The transaction valued at 274,242 led to the insider holds 42,377 shares of the business.
SAYER KEVIN R sold 49,633 shares of DXCM for $6,864,136 on Apr 08 ’24. The President CEO and Chairman now owns 283,893 shares after completing the transaction at $138.30 per share. On Mar 28 ’24, another insider, Brown Michael Jon, who serves as the EVP Chief Legal Officer of the company, sold 2,624 shares for $140.04 each. As a result, the insider received 367,472 and left with 68,682 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 50032623616 and an Enterprise Value of 49725702144. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 81.22, and their Forward P/E ratio for the next fiscal year is 55.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.11 while its Price-to-Book (P/B) ratio in mrq is 22.18. Its current Enterprise Value per Revenue stands at 13.08 whereas that against EBITDA is 58.604.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.23, which has changed by 0.06510329 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is -3.75%, while the 200-Day Moving Average is calculated to be 9.31%.
Shares Statistics:
For the past three months, DXCM has traded an average of 3.17M shares per day and 3512690 over the past ten days. A total of 396.03M shares are outstanding, with a floating share count of 387.71M. Insiders hold about 2.10% of the company’s shares, while institutions hold 96.71% stake in the company. Shares short for DXCM as of 1713139200 were 11771906 with a Short Ratio of 3.71, compared to 1710460800 on 15866558. Therefore, it implies a Short% of Shares Outstanding of 11771906 and a Short% of Float of 3.36.
Earnings Estimates
Dexcom Inc (DXCM) is currently under the scrutiny of 20.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of $0.39 for the current quarter, with a high estimate of $0.42 and a low estimate of $0.36, while EPS last year was $0.34. The consensus estimate for the next quarter is $0.52, with high estimates of $0.55 and low estimates of $0.48.
Analysts are recommending an EPS of between $1.89 and $1.67 for the fiscal current year, implying an average EPS of $1.78. EPS for the following year is $2.26, with 21.0 analysts recommending between $2.57 and $2.04.
Revenue Estimates
A total of 20 analysts believe the company’s revenue will be $1.04B this quarter.It ranges from a high estimate of $1.07B to a low estimate of $1.03B. As of the current estimate, Dexcom Inc’s year-ago sales were $841.62MFor the next quarter, 20 analysts are estimating revenue of $1.15B. There is a high estimate of $1.18B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 24 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.37B, while the lowest revenue estimate was $4.26B, resulting in an average revenue estimate of $4.33B. In the same quarter a year ago, actual revenue was $3.62BBased on 24 analysts’ estimates, the company’s revenue will be $5.16B in the next fiscal year. The high estimate is $5.4B and the low estimate is $4.97B.
